OncLive

Oncology updates, your way. 📲 Download the OncLive Insider App to access AI-driven insights, never miss a beat with breaking news alerts, and personalize your feed with saved content. Now available for iPhone and Android. Become an Insider today: ➡️ iPhone: https://hubs.li/Q03DTQFD0 ➡️ Android: https://hubs.li/Q03DTQl60

For oncology professionals, #MFN brings opportunities and challenges: Will patients see reduced costs or new barriers to care? OncLive® presents a 3-part roundtable focused on MFN’s impact on #oncologycare, reimbursement, and access to innovative therapies. Date: September 10, 2025 Time: 7:00 PM EDT Location: Live Webinar https://hubs.li/Q03GGHHp0

🚨 FDA Fast Track Alert! CER‑1236, a novel TIM‑4-targeted T-cell therapy, just scored Fast Track Designation for relapsed/refractory AML — hot on the heels of its Orphan Drug status in June. 🔬⚡ 🧬 This first-in-class engulfment receptor CAR-T aims to phagocytose tumor cells and activate the immune system — a bold new approach in AML treatment. 🧪 Now in the CertainT‑1 phase 1/1b trial, CER‑1236 is being evaluated in high-risk AML settings, including TP53-mutant disease. Read more here: https://lnkd.in/ehiAZ3Cu

Consensus recommendations from the @OncLive Bridging the Gaps in Lung Cancer 2024 meeting are now published in @JournalCancer! This article highlights strategies to advance patient care and address areas of unmet need in lung cancer. Read here: https://hubs.li/Q03H5pML0 #BTGLung #LungCancer

📢 New Lung Cancer Consensus Manuscript Published in Cancer! 🫁📝 A consensus manuscript from the BTG 2024 Lung Cancer Conference is now published in Cancer—offering 12 expert recommendations for tough clinical areas such as SCLC, leptomeningeal disease, and non-EGFR NSCLC. ➡️ Watch Narjust Florez M.D. FASCO of Dana-Farber Cancer Institute explain the significance of the publication here: https://lnkd.in/eZdW_ScZ

A new treatment option for adult patients with resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC) has been approved by the FDA. Douglas Adkins, MD, discusses the impact of this advancement within the treatment landscape. Read on: https://hubs.li/Q03GXSXR0 #SponsoredArticle

🚨 August FDA Oncology Approvals at a Glance 🚨 Last month brought 3️⃣ regulatory decisions that highlight both innovation and flexibility in cancer care: ✅ First-in-class advance: Dordaviprone (#Modeyso) became the first systemic therapy approved for H3K27M-mutant diffuse midline glioma. ✅ Targeted precision: Zongertinib #(Hernexeos) earned approval for HER2-mutant NSCLC, showing high response rates in patients with prior therapy. ✅ Treatment flexibility: A new 3-month depot formulation of leuprolide mesylate (#Camcevi ETM) was cleared for advanced prostate cancer. ⚠️ Not cleared this month ⚠️: 🚫 Daratumumab + VRd (Darzalex Faspro combo) for newly diagnosed multiple myeloma received a CRL. 🚫 Odronextamab (#Ordspono) for relapsed/refractory follicular lymphoma also received a CRL after review. 🔎 Explore the full FDA August roundup for topline trial data and expert insights into what these decisions mean for clinical practice: https://lnkd.in/dMz4ueCn

🧬 Obe-cel: A Safer, Smarter Shift in ALL Treatment? New insights from Aaron Logan, MD, PhD, and Bijal Shah, MD, MS, on OncLive On Air explore how obecabtagene autoleucel (obe-cel) is reshaping the treatment landscape for relapsed/refractory B-cell ALL. 🚀 👉Listen here: https://lnkd.in/ej8RXTa2

FDA Grants Breakthrough Therapy Designation to Zongertinib for HER2+ NSCLC 🧬💊 Zongertinib (Hernexeos), an oral HER2 TKI, has earned FDA Breakthrough Therapy Designation for 1st-line treatment of nonsquamous NSCLC with HER2 TKD mutations. 📊 From the Beamion LUNG-1 trial: ✅ 71% confirmed ORR ✅ 7% CR rate ✅ Median PFS: 12.4 months More data is on the way at WCLC & ESMO. 🔬 📖 Read the full update: FDA Grants Breakthrough Therapy Designation to Zongertinib for HER2+ NSCLC 🧬💊 Big news in lung cancer treatment: Zongertinib (Hernexeos), an oral HER2 TKI, has earned FDA Breakthrough Therapy Designation for 1st-line treatment of nonsquamous NSCLC with HER2 TKD mutations. 📊 From the Beamion LUNG-1 trial: ✅ 71% confirmed ORR ✅ 7% CRs ✅ Median PFS: 12.4 months ✅ Oral, targeted, and showing real promise This is a huge step forward for patients with a tough-to-treat mutation — and more data is on the way at WCLC & ESMO. 🔬 📖 Read the full update: 👉 https://lnkd.in/eGP669mP

🌟 Don’t miss this opportunity to learn & network! Join Drs. Manojkumar Bupathi, Eleni Efstathiou, Elizabeth Kessler & Mike Lattanzi at the OncLive State of the Science Summit on Genitourinary Cancers, taking place September 24 in Lone Tree, CO from 6-9 PM MT! Register today ➡️https://hubs.li/Q03G-vh00 Rocky Mountain Cancer Centers #SOSSConnects